Essen

• Study of efficacy and safety of LXH254 combinations in patients with previously treated unresectable or metastatic melanoma Ended recruitment
  2024-511934-11-00 4 2021-04-27 Previously treated unresectable or metastatic BRAFV600 or NRAS mutant
• Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f … Ended recruitment
  2023-507961-24-00 5 2021-04-19 High-Risk HER2-Positive Breast Cancer
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive … Ended recruitment
  2023-503568-18-00 5 2021-04-13 Early human epidermal growth factor receptor 2 (HER2) positive breast
• A Study to Evaluate the Efficacy and Safety of Crovalimab versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemog … Ended recruitment
  2023-506498-36-00 5 2021-04-08 Paroxysmal Nocturnal Hemoglobinuria (PNH)
• An Open-label study comparing 177Lu-PSMA-617 plus Standard of Care vs. Standard of Care in the Treatment of mHSPC Ended recruitment
  2023-507970-42-00 5 2021-03-31 PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)
• Inebilizumab efficacy and safety in adults with myasthenia gravis Ended recruitment
  2023-510006-40-00 5 2021-03-22 Myasthenia Gravis which is either due to acetylcholine receptor antibo
• Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Ended recruitment
  2023-507418-28-00 4 2021-03-15 Solid tumors
• Immunogenicity, safety, reactogenicity and persistence of an investigational respiratory syncytial virus (RSV) vaccine in adults aged 60 yea … Ended recruitment
  2024-512291-34-00 5 2021-02-22 Respiratory Syncytial Virus Infections
• A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis. Ended recruitment
  2022-503072-84-00 5 2021-02-13 stage IIIa cardiac AL amyloidosis
• A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis Ended recruitment
  2022-503073-11-00 5 2021-02-13 Stage IIIb cardiac AL amyloidosis
• A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab … Ended recruitment
  2022-500439-35-00 5 2021-02-11 treatment-naive chronic lymphocytic leukemia
• Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended recruitment
  2023-507263-19-00 5 2020-12-23 Advanced Non-Small Cell Lung Cancer
• A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended recruitment
  2023-504830-23-00 5 2020-12-16 B-cell Lymphoma
• A study on the efficacy and safety of cisplatin/etoposide and concomitant radiotherapy in combination with durvalumab, an immunotherapy, in … Ended recruitment
  2024-513433-20-00 4 2020-12-16 Limited Disease Small Cell Lung Cancer
• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa … Ended recruitment
  2023-506911-16-00 5 2020-12-04 ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTAT
• Multicentre, open-label, randomised, two-arm, parallel-group, superiority study to assess bioavailability and practicability of Envarsus® co … Ended recruitment
  2024-518033-28-00 6 2020-11-27 Prophylaxis of transplant rejection in adult liver allograft recipient
• A Phase 1/2, first-in-human, two-part, open-label clinical trial of intravenous administration of CTL-002 given as monotherapy and/or in com … Ended recruitment
  2024-512575-12-00 9 2020-11-25 ADVANCED-STAGE, RELAPSED/REFRACTORY SOLID TUMORS
• An extension study to learn if bepranemab (UCB0107) is safe over a long period in adults with progressive supranuclear palsy Ended recruitment
  2024-510951-36-00 3 2020-11-16 Progressive Supranuclear Palsy
• Apalutamide, Radiotherapy and LHRH Agonist in High-Risk Hormone-Sensitive Prostate Cancer Patients Assessed by PSMA-PET Ended recruitment
  2023-505852-23-00 5 2020-11-12 High risk recurrent prostate cancer previously treated with radical pr
• Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Sub … Ended recruitment
  2023-508281-15-00 1 2020-11-10 Locally Advanced or Metastatic Solid Tumors
• A Study of Atezolizumab with or without Tiragolumab in Participants with Unresectable Esophageal Squamous Cell Carcinoma whose Cancers have … Ended recruitment
  2022-502052-30-00 5 2020-10-27 Unresectable Esophageal Squamous Cell Carcinoma
• Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended recruitment
  2023-510390-33-00 5 2020-10-23 HER2-negative breast cancer patients with high relapse risk after stan
• A Clinical Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients … Ended recruitment
  2023-506576-27-00 5 2020-09-30 EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer
• A Clinical Study to Evaluate the Safety and Pharmacokinetics of JNJ- 73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or i … Ended recruitment
  2023-506577-35-00 3 2020-09-08 Advanced Non-Small Cell Lung Cancer

Showing 649–672 of 965 trials